

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number	:	<i>Unassigned</i>	Confirmation No.:	<i>Unassigned</i>
Applicant	:	WYNICK		
Filed	:	August 16, 2006		
Title	:	GALANIN RECEPTORS AND BRAIN INJURY		
TC/Art Unit	:	<i>Unassigned</i>		
Examiner:	:	<i>Unassigned</i>		
Docket No.	:	68150.000003		
Customer No.	:	21967		

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, Applicant submits herewith copies of several of the references listed on the attached Form PTO-SB/08A (modified) for consideration and to be made of record herein by the U.S. Patent and Trademark Office in the above-captioned application.

This Information Disclosure Statement (IDS) is not to be construed as a representation that a search has, or has not, been conducted or that no better art exists. The filing of this IDS is not to be construed as admission that the information cited in the IDS is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form SB/08A with the Examiner's initials in the left column in accordance with MPEP § 609 are respectfully requested.

In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted three months of the filing date of a national application other than a continued prosecution application under § 1.53(d), therefore, it is respectfully submitted that no fee is required for consideration of this information.


In the event that additional fees are deemed necessary, or in the event of any variance between the amount enclosed and the fees determined by the U.S. Patent and Trademark Office, please charge or credit any such variance to the undersigned's **Deposit Account No. 50-0206**.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: August 16, 2006

By:


Laurence H. Posorske, Ph.D.
Registration No. 34,698

Christopher J. Nichols, Ph.D.
Registration No. 55,984

Hunton & Williams LLP
Intellectual Property Department
1900 K Street, N.W. Suite 1200
Washington, DC 20006
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)

LHP/CJN:cdh

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number *Unassigned*

Filing Date August 16, 2006

First Named Inventor David WYNICK

Art Unit *Unassigned*Examiner Name *Unassigned*

Sheet 1 of 1 Attorney Docket Number 68150.000003

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US- 20030009777	01-09-2003	WYNICK	
	2.	US-			

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code:	Number - Kind Code (if known)				YES	NO
	3.	WO	WO 98/03059	01-29-1998	WYNICK		<input type="checkbox"/>	<input type="checkbox"/>
	4.	WO					<input type="checkbox"/>	<input type="checkbox"/>
	5.	WO					<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION
			YES NO
	6.	Mahoney et al. (January 15, 2003) "The second galanin receptor GalR2 plays a key role in neurite outgrowth from adult sensory neurons." <u>Journal of Neuroscience</u> 23(2): 416-421	<input type="checkbox"/> <input type="checkbox"/>
	7.	Mahoney et al. (August 23, 2003) "The galanin antagonist M35 has intrinsic agonistic activity in the dorsal root ganglion." <u>Neuroreport</u> 14(12): 1649-1652	<input type="checkbox"/> <input type="checkbox"/>
	8.	Liu et al. (August 14, 2001) "Receptor subtype-specific pronociceptive and analgesic actions of galanin in the spinal cord: Selective actions via GalR1 and GalR2 receptors." <u>PNAS</u> 98(17): 9960-9964	<input type="checkbox"/> <input type="checkbox"/>
	9.	Elliot-Hunt et al. (April 6, 2004) "Galanin acts as a neuroprotective factor in the hippocampus." <u>PNAS</u> 101(6): 5105-5110	<input type="checkbox"/> <input type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.